Hepatorenal Syndrome Predictors and Management

Pathophysiological Mechanisms

The development of hepatorenal syndrome involves splanchnic vasodilation leading to reduced effective arterial blood volume and decreased mean arterial pressure, according to the European Association for the Study of the Liver 2
Activation of the sympathetic nervous system and renin-angiotensin-aldosterone system causes renal vasoconstriction, as stated by the European Association for the Study of the Liver 2
Impairment of cardiac function due to cirrhotic cardiomyopathy contributes to the development of hepatorenal syndrome, as noted by the European Association for the Study of the Liver 2
Systemic inflammation, adrenal dysfunction, and intra-abdominal hypertension are also key factors in the development of hepatorenal syndrome, according to the American Association for the Study of Liver Diseases 1
Increased synthesis of vasoactive mediators affects renal blood flow, as reported by the European Association for the Study of the Liver 2

The diagnosis of hepatorenal syndrome requires a serum creatinine level >1.5 mg/dL, as recommended by the International Club of Ascites 2
The absence of shock is a necessary criterion for the diagnosis of hepatorenal syndrome, according to the International Club of Ascites 2
No improvement in renal function after at least 2 days of diuretic withdrawal and volume expansion with albumin is required for the diagnosis, as stated by the International Club of Ascites 2
The absence of parenchymal renal disease, as indicated by proteinuria <0.5 g/day, no microhematuria, and normal renal ultrasound, is necessary for the diagnosis of hepatorenal syndrome, according to the International Club of Ascites 2

The median survival of all patients with hepatorenal syndrome is approximately 3 months, as reported by the European Association for the Study of the Liver 2
Untreated type 1 hepatorenal syndrome has a median survival of approximately 1 month, according to the European Association for the Study of the Liver 2

Albumin infusion with therapeutic paracentesis can help prevent hepatorenal syndrome development, as recommended by the American Association for the Study of Liver Diseases 1
Antibiotic prophylaxis against spontaneous bacterial peritonitis can reduce the risk of developing hepatorenal syndrome, according to the American Association for the Study of Liver Diseases 1
Prompt treatment of spontaneous bacterial peritonitis with albumin and antibiotics reduces the risk of developing hepatorenal syndrome, as stated by the European Association for the Study of the Liver 2
Avoidance of nephrotoxic medications, such as NSAIDs, ACE inhibitors, and ARBs, is recommended to prevent hepatorenal syndrome, according to the American Association for the Study of Liver Diseases 1

Withdrawal of diuretics and nephrotoxic drugs is necessary in the management of hepatorenal syndrome, as recommended by the American Association for the Study of Liver Diseases 1
Administration of albumin, at a dose of 1 g/kg on the first day, followed by 20-40 g/day, is recommended for the management of hepatorenal syndrome, according to the American Association for the Study of Liver Diseases 1
Treatment of underlying infections is crucial in the management of hepatorenal syndrome, as stated by the American Association for the Study of Liver Diseases 1
Consideration of vasoconstrictors for stage ≥2 AKI or stage 1 with creatinine >1.5 mg/dL may be necessary in the management of hepatorenal syndrome, according to the American Association for the Study of Liver Diseases 1 and the European Association for the Study of the Liver 3
Monitoring for fluid overload when administering albumin is necessary due to the risk of pulmonary edema, as recommended by the American Association for the Study of Liver Diseases 1
Consideration of liver transplantation as the definitive treatment for hepatorenal syndrome is recommended, according to the American Association for the Study of Liver Diseases 1